Back to search
FDAFDA · Food and drugs·Recall number D-1303-2022

Matzim LA (Diltiazem Hydrochloride) Extended-Release Tablets, 240 mg, 30-count bottles, Rx Only, Manufactured by: Actavis Laboratories FL, Inc., Fort Lauderdale, FL USA 33314, USA, Distributed by: Actavis Pharma Inc., Parsippany, NJ 07054 USA; NDC 58544-692-30.

Published August 10, 2022 · Recall initiated: July 21, 2022

Summary

FDA records drug Class II recall D-1303-2022, published August 10, 2022 and initiated July 21, 2022. Recalling firm: Teva Pharmaceuticals USA Inc; Status: Terminated; Reported quantity: 5677 bottles; Lot: Lot 1411596A, Exp 09/22. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Dissolution Specifications: below specification limits for dissolution.

What to do

Voluntary: Firm initiated

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Teva Pharmaceuticals USA Inc
Distributor
Nationwide in the USA and Puerto Rico
Lot
Lot 1411596A, Exp 09/22
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Matzim LA (Diltiazem Hydrochloride) Extended-Release Tablets, 240 mg, 30-count bottles, Rx Only, Manufactured by: Actavis Laboratories FL, Inc., Fort Lauderdale, FL USA 33314, USA, Distributed by: Actavis Pharma Inc., Parsippany, NJ 07054 USA; NDC 58544-692-30. recalled?

Yes. FDA published recall D-1303-2022 on August 10, 2022. Reported hazard: Failed Dissolution Specifications: below specification limits for dissolution.

What should I do if I have this product?

Voluntary: Firm initiated